Title:
癌のエピジェネティックプロファイリング
Document Type and Number:
Japanese Patent JP7189020
Kind Code:
B2
Abstract:
The present invention relates to a method for determining the presence or absence of at least one super-enhancer in a cancerous biological sample based on signal intensity of the histone modification H3K27ac. The present invention also relates to a method for determining the prognosis of cancer in a subject, a method of determining the susceptibility of a subject to cancer or a gastrointestinal disease and a method of predicting cancer cell survival or cancer cell viability by determining the presence or absence of at least one super-enhancer. The present invention also relates to inhibitors of CDX2 and/or HNF4α, such as metformin, and use thereof for modulating the activity of a super-enhancer.
More Like This:
Inventors:
Tampatrick
Ooi Wen Fong
Ooi Wen Fong
Application Number:
JP2018543192A
Publication Date:
December 13, 2022
Filing Date:
February 16, 2017
Export Citation:
Assignee:
Agency for Science, Technology and Research
International Classes:
C12Q1/6869; A61K31/713; A61K45/00; A61K48/00; A61P35/00; A61P43/00; C12N15/113; G01N33/574
Foreign References:
| US20140287932 |
Other References:
CHANG, H. R. et al.,HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer,Gut,2014年11月19日,Vol. 65, No. 1,P. 19-32
LEE, H.-J. et al.,Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early-stage gastric cancer,Gastroenterology,2010年,Vol.139, No.1,P.213-225
LEE, H.-J. et al.,Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early-stage gastric cancer,Gastroenterology,2010年,Vol.139, No.1,P.213-225
Attorney, Agent or Firm:
Kazuko Fujita